Resume (Education and Working Experience)

Education：

1. 2013 Peking University Bachelor of Science
2. 2015 Peking University Master of Science
3. 2019 Peking University Doctor of Philosophy

Working Experience：

1. 2019-2020 Associate Researcher, Mengchao Hepatobiliary Hospital of Fujian Medical University

2. 2020-2022 Postdoctor, Hong Kong Baptist University (School of Chinese Medicine)

3. 2022-2025 Research Assistant Professor, Hong Kong Baptist University (School of Chinese Medicine)

4. 2025- Research Assistant Professor, The Chinese University of Hong Kong (School of Chinese Medicine)

Research interests：

1. Aptamer-Functionalized Chinese Medicine in the Field of Anti-Tumor Therapy
2. Development of Chinese Medicine Based on Targeted Protein Degradation Technology

Publications：

1. Jiang Hewen, Tao Xiaohui, Yu Sifan, Zhang Yihao, Ma Yuan (co-first author), Li Nanxi, Wang Shenghang, Zhang Ning, Yang Xin, Ding Shijian, Zhong Chuanxin, Li Haitian, Li Zhanghao, Wen Xiaoxin, Zhang Huarui, Chen Zefeng, Sun Meiheng, Luo Hang, Ren Meishen, Lei Chongguang, Yu Yuanyuan, Liu Jin, Zhang Zongkang, Lyu Aiping, Sheng Hui, Li Dijie, Wang Luyao, Zhang Ge, Zhang Baoting. Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism. Nat Commun 2026, 17, 1812.
2. Ma Yuan, Amu Gubu, Pan Yufei, Jiang Hewen, Yu Sifan, Zhang Huarui, Chen Zefeng, Luo Hang, Zhong Chuanxin, Yang Xin, Tao Xiaohui, Zhang Yihao, Yu Yuanyuan, Lu Aiping, Wang Luyao, Zhang Baoting, Zhang Ge. Harnessing Bone-Liver Crosstalk: A Dual-Action LYTAC Approach for Bone-Specific Accumulation and Liver-Specific Protein Degradation in Bone Disorders. JACS Au 2025, 5, 5973-5984.
3. Luo Hang, Tian Yuan, Abdullah Razack, Zhang Baoting, Ma Yuan (co-corresponding author), Zhang Ge. Advancing Design Strategy of PROTACs for Cancer Therapy. MedComm 2025, 6 (7), e70258.
4. Amu Gubu, Yang Xin, Luo Hang, Yu Sifan, Zhang Huarui, Tian Yuan, Yu Yuanyuan, Ding Shijian, Pan Yufei, Chen Zefeng, He Yixin, Ma Yuan (co-first author & co-corresponding author), Zhang Baoting, Zhang Ge. Machine learning-powered, high-affinity modification strategies for aptamers. Acta Materia Medica 2025, 4 (1), 122-136.
5. Shen Xinyang, Ma Yuan (co-first author), Luo Hang, Abdullah Razack, Pan Yufei, Zhang Yihao, Zhong Chuanxin, Zhang Baoting, Zhang Ge. Peptide Aptamer-Paclitaxel Conjugates for Tumor Targeted Therapy. Pharmaceutics 2025, 17 (1), 40.
6. Ma Yuan, Zhang Huarui, Shen Xinyang, Yang Xin, Deng Yan, Tian Yuan, Chen Zefeng, Pan Yufei, Luo Hang, Zhong Chuanxin, Yu Sifan, Lu Aiping, Zhang Baoting, Tang Tao, Zhang Ge. Aptamer Functionalized Hypoxia-potentiating Agent and Hypoxia-inducible Factor Inhibitor Combined with Hypoxia-activated Prodrug for Enhanced Tumor Therapy. Cancer Lett 2024, 598, 217102.
7. Amu Gubu, Zhang Ge, Jing Nanan, Ma Yuan (corresponding author). Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics. J Med Chem 2024, 67 (21), 18883-18894.

8. Ma Yuan, Xie Duoli, Chen Zefeng, Shen Xinyang, Wu Xiaoqiu, Ding Feng, Ding Shijian, Pan Yufei, Li Fangfei, Lu Aiping, Zhang Ge. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release. J Transl Med 2024, 22 (1), 604.

9. Amu Gubu, Ma Yuan (co-first & co-corresponding author), Yu Sifan, Zhang Huarui, Chen Zefeng, Ni Shuaijian, Abdullah Razack, Xiao Huan, Zhang Yihao, Dai Hong, Luo Hang, Yu Yuanyuan, Wang Luyao, Jiang Hewen, Zhang Ning, Tian Yuan, Li Haitian, Lu Aiping, Zhang Baoting, Zhang Ge. Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential. Mol Ther Nucleic Acids 2024, 35 (1), 102146.

10. Pan Yufei, Wang Quanxin, Ma Yuan (corresponding author), Small RNAs in Cancer Therapy. In Interdisciplinary Cancer Research, Springer International Publishing: Cham, 2024; pp 1-27.

11. Zhang Huarui, Yu Sifan, Ni Shuaijian, Gubu Amu, Ma Yuan (co-first author), Zhang Yihao, Li Haitian, Wang Yuzhe, Wang Luyao, Zhang Zongkang, Yu Yuanyuan, Lyu Aiping, Zhang Baoting, Zhang Ge. A bimolecular modification strategy for developing long-lasting bone anabolic aptamer. Mol Ther Nucleic Acids 2023, 34 (18), 102073.

12. Amu Gubu, Zhang Xueli, Lu Aiping, Zhang Baoting, Ma Yuan (co-corresponding author), Zhang Ge. Nucleic acid amphiphiles: synthesis, properties and applications. Mol Ther Nucleic Acids 2023, 33, 144-163.

13. Chen Zefeng, Luo Hang, Gubu Amu, Yu Sifan, Zhang Huarui, Dai Hong, Zhang Yihao, Zhang Baoting, Ma Yuan (co-corresponding author), Lu Aiping, Zhang Ge. Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding. Front Cell Dev Biol 2023, 11, 1091809.

14. Ma Yuan, Zhang Yihao, Chen Zefeng, Tian Yuan, Zhang Ge, The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates. In Drug Metabolism and Pharmacokinetics, Mithun Rudrapal, Ed. IntechOpen: Rijeka, 2023; p Ch. 6.

15. Ma Yuan, Yu Yuanyuan, Zhang Baoting, Lu Aiping, Zhang Ge. Editorial: Aptamer-based structural biology, computational modelling, translational research and drug discovery, Volume II. Front Cell Dev Biol 2023, 11, 1195372.

16. Dai Hong, Abdullah Razack, Wu Xiaoqiu, Li Fangfei, Ma Yuan (co-corresponding author), Lu Aiping, Zhang Ge. Pancreatic cancer: Nucleic acid drug discovery and targeted therapy. Front Cell Dev Biol 2022, 10, 855474.

17. Xue Fangqin, Lin Xiao, Cai Zhixiong, Liu Xiaolong, Ma Yuan (co-corresponding author), Wu Ming. Doxifluridine-based pharmacosomes delivering mir-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma. Colloids Surf B Biointerfaces 2021, 197, 111367.

18. Ma Yuan, Yu Sifan, Ni Shuaijian, Zhang Baoxian, Kung Angela Chun Fai, Gao Jin, Lu Aiping, Zhang Ge. Targeting strategies for enhancing paclitaxel specificity in chemotherapy. Front Cell Dev Biol 2021, 9, 626910.

19. Ma Yuan, Zhao Wenting, Li Yiding, Pan Yufei, Wang Shuhe, Zhu Yuejie, Kong Lingxuan, Guan Zhu, Wang Jiancheng, Zhang Lihe, Yang Zhenjun. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo. Biomaterials 2019, 197, 182-193.

20. Ma Yuan, Zhu Yuejie, Wang Chao, Pan Delin, Liu Shuang, Yang Mengyi, Xiao Zhangping, Yang Xiantao, Zhao Wenting, Zhou Xinyang, Li Yiding, Pan Yufei, Sun Jing, Wang Shuhe, Guan Zhu, Zhang Lihe, Yang Zhenjun. Annealing novel nucleobase-lipids with oligonucleotides or plasmid DNA based on H-bonding or π-π interaction: Assemblies and transfections. Biomaterials 2018, 178, 147-157.